Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Assets: 2010-2024

Historic Current Assets for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $137.3 million.

  • Altimmune's Current Assets rose 48.61% to $216.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.6 million, marking a year-over-year increase of 48.61%. This contributed to the annual value of $137.3 million for FY2024, which is 34.52% down from last year.
  • Altimmune's Current Assets amounted to $137.3 million in FY2024, which was down 34.52% from $209.6 million recorded in FY2023.
  • Over the past 5 years, Altimmune's Current Assets peaked at $230.3 million during FY2020, and registered a low of $137.3 million during FY2024.
  • In the last 3 years, Altimmune's Current Assets had a median value of $192.8 million in 2022 and averaged $179.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 484.49% in 2020, then slumped by 34.52% in 2024.
  • Yearly analysis of 5 years shows Altimmune's Current Assets stood at $230.3 million in 2020, then fell by 11.35% to $204.1 million in 2021, then dropped by 5.54% to $192.8 million in 2022, then rose by 8.72% to $209.6 million in 2023, then plummeted by 34.52% to $137.3 million in 2024.